Session: FP36-Ovarian & Uterine Function
Room 104 (Moscone Center)
Poster Board MON-572
Aim: to determine if kisspeptin can effectively induce oocyte maturation in women undergoing IVF treatment.
Study design: 10 women underwent a modified FSH/GnRH antagonist IVF protocol using kisspeptin in place of hCG to trigger oocyte maturation. Subcutaneous (sc) daily injections of FSH (Gonal F 150iu) was started from menstrual day 2, and GnRH antagonist (Cetrotide 0.25mg; to inhibit a premature LH surge) was commenced when the lead follicle >14mm, and stopped when 3 ovarian follicles ≥18mm diameter had developed. Kisspeptin-54 (sc bolus 1.6, 3.2, 6.4 or 12.8nmol/kg, n=2-3/dose) was administered 24hrs after the last GnRH antagonist injection. Oocytes were retrieved 36hrs after kisspeptin injection. Following intracytoplasmic sperm injection (ICSI), 1 or 2 embryos were transferred to the uterine cavity. Primary outcome: number of mature oocytes (oocytes in metaphase II; MII).
Results: Kisspeptin resulted in a 7.1±1.9-fold (mean±SEM) increase in LH release 12h following injection. Oocyte maturation was observed at all doses of kisspeptin (9/10 women had oocyte maturation [mean±SEM number of MII oocytes 6.1±1.2]). Embryogenesis occurred in 8/10 women following kisspeptin (mean±SEM 2.8±0.74). Pregnancy data is awaited but to date 1 woman already has a successful ongoing pregnancy and is currently 27 weeks pregnant with a single foetus and no anomalies detected at the 20 week ultrasound scan.
Conclusion: We show for the first time that kisspeptin can effectively induce oocyte maturation in IVF treatment. Kisspeptin may therefore offer an entirely novel therapeutic option for fertility treatment.
Nothing to Disclose: AA, CNJ, GMN, ANC, GC, DA, MAG, SRB, AC, GT, WSD
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters